Shares of Juniper Pharmaceuticals, a specialty pharmaceutical company focused on developing therapeutics that address unmet medical needs in women’s health, saw its shares rise after the company announced a definitive agreement with Catalent, Inc. The stock jumped a little over 31% after Juniper said that Catalent will acquire all of the outstanding shares of the … Continue reading “Juniper Pharmaceuticals Soars on Catalent Buy Out”
